Biosimilars Business Roundup for August 2024—Podcast Edition

On this episode of Not So Different, the end of the second quarter brings with it expense reports, new biosimilar business deals, and insights into how federal policy impacts biosimilar company pursuits.

Show notes

1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024

2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024

3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars

4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel

5. FDA Approves Biosimilar Enzeevu for Eye Conditions

6. Manitoba Adopts Biosimilar Switching Policy

7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results

8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline